GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Contract chipmaker GlobalFoundries has appointed Tim Breen as its chief executive officer, the company said on Wednesday.

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

Total Q4 sales GBP 8.12B up 1% AER; up 4% CER. Vaccines sales down 12%. Specialty Medicines sales up 17%. HIV sales up 14%. Oncology up 72%.

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to ...

GSK (GSK.L, GSK) reported fiscal 2024 profit before tax of 3.5 billion pounds, down 43% at AER, or down 34% at CER from prior year.

GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...

Final investment decisions had been made for the Tarbert Next (LON: NXT) Generation biopower station in Co Kerry and the ...